HemoBioTech, Inc. to Present Blood Substitute Strategy at RENN Capital Investor Conference
5/15/2009 10:20:59 AM
DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB:HMBT) (www.hemobiotech.com) announced today that Dr. Arthur P. Bollon, Chairman & CEO, will present the development strategy for its blood substitute, HemoTech, at the RENN Capital Investor Conference on May 15, 2009. Dr. Bollon will discuss the global need for a safe blood substitute as an alternative to contaminated blood. About 10% of new HIV/AIDS cases are due to HIV contaminated blood globally. RENN Capital is the leading institutional investor in HemoBioTech.
comments powered by